Tag: Synaffix
Synaffix Expands Licensing Agreement with Mersana
The Netherlands-based Synaffix, a biotechnology company focusing on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed the expansions of...
The 7th Annual World ADC Awards Winners – What’s Next
The World ADC Awards showcase companies, teams, and individuals in the industry, across 9 categories, at the forefront of cancer research today. Finalists and...
In vivo data Shows Efficacy of Synaffix’ Proprietary Exatecan Linker-Payload to...
In a poster presented during the virtual World ADC meeting, being held September 15 - 17, 2020 scientists at Synaffix showed early in vivo...
Synaffix and ADC Therapeutics Expand Collaboration
The Netherlands-based biotechnology company Synaffix and Swiss-based ADC Therapeutics have expanded the existing collaboration between the companies to explore additional applications of Synaffix’ site-specific...
Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement
Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology company with a clinical-stage pipeline...
Abzena Confirms Successful Technical Transfer of Synaffix’s GlycoConnect™ and HydraSpace™ Technologies
Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies of GlycoConnect™, site-specific antibody-drug conjugation...
ADC Therapeutics Expands Agreement with Synaffix
The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered...
Dutch Biotech Signs License Agreement with Chinese ADC Developer
The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement is estimated to be worth...
First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate...
The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing of the first patient in...
Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...
Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...
